TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39474856

Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling device offered by a midwife
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling device
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Questionnaires on socio-economic environment and motivational factors
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with a sub-group
Number of subjects: 600
Study: 39474983

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve edge-to-edge repair (T-TEER)
Number of subjects: 1230
Study: 39475112

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir treatment
Number of subjects: 501
Study: 39475143

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (up to 64 Units)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study: 39475399

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid-valve replacement and medical therapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Medical therapy alone (control group)
Number of subjects: 400
Study: 39475416

Group type: EXPERIMENTAL
Intervention: Reinforced tension-line (RTL) suture with 4 : 1 small-bite closure with polypropylene sutures (RTL group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 4 : 1 small-bite closure with polydioxanone suture alone (PDS group)
Number of subjects: 160
Study: 39475418

Group type: EXPERIMENTAL
Intervention: palbociclib + endocrine therapy (ET) in first-line (1L) setting
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: palbociclib + endocrine therapy (ET) in second-line or later (≥2L) setting
Number of subjects: 1250
Study: 39475591

Group type: EXPERIMENTAL
Intervention: Onvansertib in combination with FOLFIRI + bevacizumab
Number of subjects: 53
Study: 39475817

Group type: EXPERIMENTAL
Intervention: Dapagliflozin, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 39475834

Group type: EXPERIMENTAL
Intervention: Double-point serratus anterior plane block (SAPB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-point serratus anterior plane block (SAPB)
Number of subjects: 60
Study: 39475840

Group type: EXPERIMENTAL
Intervention: Inner Dragon game
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control (Smoke Free app core features)
Number of subjects: 500
Study: 39475855

Group type: EXPERIMENTAL
Intervention: Multidimensional educational intervention covering healthy, sustainable nutrition and lifestyle.
Number of subjects: 227
Study: 39475852

Group type: EXPERIMENTAL
Intervention: Multimodal Digital Behavior Change Intervention (DBCIs) including a scale, smartphone app, activity tracker, video library, and on-demand health coach.
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Multimodal Digital Behavior Change Intervention (DBCIs)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Standard employer-provided health and wellness benefits (Control)
Number of subjects: 603
Study: 39475860

Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Supplement (MIS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Collagen Control (COL)
Number of subjects: 26
Study: 39475859

Group type: EXPERIMENTAL
Intervention: Whole-body resistance exercise (RE) - 4 sets of 4 different exercises at 70% 1-repetition maximum with the last set to failure
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole-body resistance exercise (RE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 16
Study: 39475960

Group type: EXPERIMENTAL
Intervention: 6-, 11-, or 22-mg/day upadacitinib for 24 weeks
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 6-, 11-, or 22-mg/day upadacitinib
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 39475978

Group type: EXPERIMENTAL
Intervention: 3D ultrasonography with 3D picture
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 3D ultrasonography with 3D model
Number of subjects: 33

Group type: COMPARATOR
Intervention: 3D ultrasonography (either intervention)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Reduction in cigarette use
Number of subjects: 33
Study: 39476073

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) targeting the prefrontal cortex, 5 days a week for 8 weeks followed by twice-a-year 5-day boosters and daily at-home CR.
Number of subjects: 375

Group type: COMPARATOR
Intervention: Sham plus sham intervention.
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) targeting the prefrontal cortex.
Number of subjects: 375
Study: 39476101

Group type: EXPERIMENTAL
Intervention: Thrombopoietin receptor agonists
Number of subjects: 48
Study: 39476124

Group type: EXPERIMENTAL
Intervention: Forimtamig (GPRC5D-targeting T-cell bispecific antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forimtamig in combination with standard-of-care agents (anti-CD38 antibodies, immunomodulatory drugs, proteasome inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forimtamig in combination with novel therapeutic agents (BCMA-TCB and CELMoDs)
Number of subjects: 0
Study: 39476204

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Maintenance phase with CPX-351
Number of subjects: 29
Study: 39476237

Group type: EXPERIMENTAL
Intervention: Virtual Breakthrough Series (VBTS) intervention
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Site with lowest follow-up rate
Number of subjects: 11
Study: 39476303

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) alone
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD) alone
Number of subjects: 501
Study: 39476339

Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide (2.4 mg)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 39476340

Group type: EXPERIMENTAL
Intervention: Inavolisib plus palbociclib-fulvestrant
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo plus palbociclib-fulvestrant
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Inavolisib
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 39476341

Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 109

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 109
Study: 39476739

Group type: EXPERIMENTAL
Intervention: Probiotic toothpaste containing Lactobacillus paracasei, used twice a day for four weeks.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Regular toothpaste (Colgate), used twice a day for four weeks.
Number of subjects: 44
Study: 39476808

Group type: EXPERIMENTAL
Intervention: Nutritional counseling program for mothers based on UNICEF dietary guidelines, followed by monthly phone calls
Number of subjects: 516

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 516
Study: 39477026

Group type: EXPERIMENTAL
Intervention: Lugol's chromoendoscopy (LCE) + High-resolution microendoscopy (HRME)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Lugol's chromoendoscopy (LCE)
Number of subjects: 916
Study: 39477171

Group type: EXPERIMENTAL
Intervention: IV rt-PA
Number of subjects: 3332

Group type: COMPARATOR
Intervention: No IV rt-PA
Number of subjects: 3332
Study: 39477187

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Olaparib
Number of subjects: 851

Group type: COMPARATOR
Intervention: Pembrolizumab plus Placebo
Number of subjects: 851
Study: 39477271

Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia (CIN)2+ prevalence in women with HIV aged 30-49 (15.9%) vs 50+ (19.3%)
Number of subjects: 4090

Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia (CIN)2+ prevalence in women without HIV aged 30-49 (13.3%) vs 50+ (10.4%)
Number of subjects: 4090

Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia (CIN)3+ prevalence in women with HIV aged 30-49 vs 50+
Number of subjects: 4090

Group type: EXPERIMENTAL
Intervention: Cervical intraepithelial neoplasia (CIN)3+ prevalence in women without HIV aged 30-49 vs 50+
Number of subjects: 4090

Group type: EXPERIMENTAL
Intervention: Cervical cancer diagnoses in women aged 50+
Number of subjects: 4090
Study: 39477275

Group type: EXPERIMENTAL
Intervention: Iodised salt fortified with 30 ppm folic acid to provide ~200 µg folic acid/day
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Iodised salt fortified with 90 ppm folic acid to provide ~600 µg folic acid/day
Number of subjects: 360

Group type: COMPARATOR
Intervention: Iodised salt (comparator)
Number of subjects: 360
Study: 39477487

Group type: EXPERIMENTAL
Intervention: BFR-enhanced programme
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional exercise programme
Number of subjects: 120
Study: 39477631

Group type: EXPERIMENTAL
Intervention: Standard-of-care (SoC) therapy withdrawal
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard-of-care (SoC) therapy (not withdrawn)
Number of subjects: 145
Study: 39477819

Group type: EXPERIMENTAL
Intervention: At-home screening without provider encouragement
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: At-home screening with provider encouragement
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: In-clinic screening with provider encouragement
Number of subjects: 627

Group type: COMPARATOR
Intervention: Clinic setting (control)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: White patients (all groups)
Number of subjects: 627
Study: 39477835

Group type: EXPERIMENTAL
Intervention: APT-weighted imaging
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: APT-weighted LD mapping
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional GTV
Number of subjects: 9
Study: 39477924

Group type: EXPERIMENTAL
Intervention: 4-month rifapentine-moxifloxacin regimen
Number of subjects: 0
Study: 39478168

Group type: EXPERIMENTAL
Intervention: NMDAR1-abs seropositive patients
Number of subjects: 569
Study: 39478450

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program based on Wellness Motivation Theory (WMT), performed three times a week for 24 weeks
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program based on Wellness Motivation Theory (WMT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: One-time advice on physical activity
Number of subjects: 144
Study: 39478521

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine infusion (5 μg/kg/min) for 24 hours after PCI
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (NaCl) for 24 hours after PCI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 100
Study: 39478532

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily for 12 weeks, then open-label nintedanib for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 12 weeks, then open-label nintedanib for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39478564

Group type: EXPERIMENTAL
Intervention: Exercise oncology service
Number of subjects: 0
Study: 39478609

Group type: EXPERIMENTAL
Intervention: TKA with tourniquet
Number of subjects: 81

Group type: COMPARATOR
Intervention: TKA without tourniquet
Number of subjects: 81
Study: 39478644

Group type: EXPERIMENTAL
Intervention: Nanohydroxyapatite (NHA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 24
Study: 39478672

Group type: EXPERIMENTAL
Intervention: TDF + PegIFN
Number of subjects: 93

Group type: COMPARATOR
Intervention: TDF alone
Number of subjects: 93
Study: 39478814

Group type: EXPERIMENTAL
Intervention: Combination of home-based exercise and pulsed electromagnetic field (PEMF) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Home-based exercise alone (control group)
Number of subjects: 60
Study: 39479003

Group type: EXPERIMENTAL
Intervention: Acute cerebrovascular dysfunction measured using multimodal non-invasive neuromonitoring (transcranial Doppler and cerebral near-infrared spectroscopy) within 7-days of onset of TBI.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cerebrovascular dysfunction severity during acute phase.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Recovery from cerebrovascular dysfunction.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cognitive/functional assessments (Glasgow Outcome Scale and Patient-Reported Outcomes Measurement Information System) at follow-ups 3-, 6-, and 12-months post-injury.
Number of subjects: 130
Study: 39479005

Group type: EXPERIMENTAL
Intervention: 40Hz gamma sensory stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 39479199

Group type: EXPERIMENTAL
Intervention: Eye color (specific colors not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39479329

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 111
Study: 39479373

Group type: EXPERIMENTAL
Intervention: Amaze™ asthma disease management platform
Number of subjects: 159
Study: 39479758

Group type: EXPERIMENTAL
Intervention: AWARE intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 103
Study: 39479862

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Conventional second-line chemotherapy
Number of subjects: 334
Study: 39480040

Group type: EXPERIMENTAL
Intervention: Poly l-lactic acid (PLLA-SCA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Calcium hydroxylapatite (CaHA-R)
Number of subjects: 21
Study: 39480129

Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 39480221

Group type: EXPERIMENTAL
Intervention: Intraosseous access
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Intravenous access
Number of subjects: 1479
Study: 39480285

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Services as usual (SAU)
Number of subjects: 0
Study: 39480364

Group type: EXPERIMENTAL
Intervention: Eigen radiomic features
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Clinical model incorporating cardiovascular risk score, Agatston score, and presence of obstructive coronary artery disease
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Model including eigen radiomic features
Number of subjects: 1750
Study: 39480379

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 1720

Group type: COMPARATOR
Intervention: Control second-generation drug-eluting stent (DES)
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography substudy
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: Angiography substudy
Number of subjects: 1720
Study: 39480380

Group type: EXPERIMENTAL
Intervention: TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical therapy (OMT)
Number of subjects: 392

Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 392
Study: 39480391

Group type: EXPERIMENTAL
Intervention: Cryoballoon or Radiofrequency Ablation
Number of subjects: 346
Study: 39480422

Group type: EXPERIMENTAL
Intervention: Clinician peer comparison
Number of subjects: 509269

Group type: EXPERIMENTAL
Intervention: Patient informational mail
Number of subjects: 509269

Group type: EXPERIMENTAL
Intervention: Combination of clinician peer comparison and patient informational mail
Number of subjects: 509269

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 509269

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 509269
Study: 39480424

Group type: EXPERIMENTAL
Intervention: Low-magnitude mechanical signals (LMMS) (0.3 g at 32-37 Hz) for 10 minutes daily for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham (placebo) signals for 10 minutes daily for 6 months
Number of subjects: 40
Study: 39480453

Group type: EXPERIMENTAL
Intervention: Veliparib (40 mg orally, twice daily, days 1-7) combined with temozolomide (150-200 mg/m2 orally, days 1-5) for 6 cycles
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo combined with temozolomide (150-200 mg/m2 orally, days 1-5) for 6 cycles
Number of subjects: 447
Study: 39480493

Group type: EXPERIMENTAL
Intervention: PROMIS® report cards (Arm 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (Arm 2)
Number of subjects: 110
Study: 39480530

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI every 2 weeks with routine G-CSF prophylaxis
Number of subjects: 92
Study: 39480645

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 511
Study: 39480670

Group type: EXPERIMENTAL
Intervention: Various methods for assessing volume overload and congestion including plasma biomarkers, measurement of blood volume from [131I]-human serum albumin, sonographic modalities, implantable devices, invasive measurements (right heart catheterization), and impedance methods.
Number of subjects: 0
Study: 39480764

Group type: EXPERIMENTAL
Intervention: Tegoprubart (anti CD40L antibody) administered intravenously, 6 infusions every 2 weeks at doses of 1 mg/kg, 2 mg/kg, 4 mg/kg, and 8 mg/kg
Number of subjects: 54
Study: 39480784

Group type: EXPERIMENTAL
Intervention: Audiobook mobile application (poetry) for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pre-intervention evaluation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-intervention evaluation
Number of subjects: 60
Study: 39480792

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation combined with lumbo-pelvic stability core training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 40
Study: 39480821

Group type: EXPERIMENTAL
Intervention: Digital self-efficacy training combined with ecological momentary assessment (EMA)
Number of subjects: 93

Group type: COMPARATOR
Intervention: EMA only (control group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Digital self-efficacy training
Number of subjects: 93
Study: 39480988

Group type: COMPARATOR
Intervention: Glucagon-Like Peptide-1 Receptor Agonists
Number of subjects: 0
Study: 39481054

Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin (EV) 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle
Number of subjects: 46
Study: 39481070

Group type: EXPERIMENTAL
Intervention: Intervention group (cryptogenic stroke patients)
Number of subjects: 878
Study: 39481328

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula at 30 L/min (HFNC-30)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula at 50 L/min (HFNC-50)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 137
Study: 39481395

Group type: EXPERIMENTAL
Intervention: Camizestrant 75 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Camizestrant 150 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fulvestrant 500 mg
Number of subjects: 240
Study: 39481425

Group type: EXPERIMENTAL
Intervention: DynamX bioadaptor (Elixir Medical)
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Zotarolimus-eluting DES (Resolute Onyx and Onyx Trustar, Medtronic)
Number of subjects: 2399
Study: 39481541

Group type: EXPERIMENTAL
Intervention: Mungbean dal with fresh guava (3.2 mg iron; ∼170 mg vitamin C; molar ratio ∼18:1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mungbean dal only (3.0 mg iron; vitamin C:iron molar ratio ∼0.5:1)
Number of subjects: 200
Study: 39481576

Group type: EXPERIMENTAL
Intervention: EUS-guided shear wave elastography (EUS-SWE)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fibrosis-4 Index (FIB-4)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vibration-controlled transient elastography (VCTE)
Number of subjects: 62
Study: 39481880

Group type: EXPERIMENTAL
Intervention: neoadjuvant platinum-based chemotherapy followed by surgery
Number of subjects: 743
Study: 39482336

Group type: EXPERIMENTAL
Intervention: Inhaled Recombinant COVID-19 Vaccine (Ad5-nCoV-IH)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Intramuscular tozinameran (BNT-IM)
Number of subjects: 540
Study: 39482393

Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional treadmill training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 39482484

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin 2 (Ld-IL2) therapy along with standard treatment for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 60
Study: 39482707

Group type: EXPERIMENTAL
Intervention: Integrated model using cfDNA methylation patterns, protein profiling, and CT imaging features
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Integrated model
Number of subjects: 419

Group type: COMPARATOR
Intervention: Individual methylation model
Number of subjects: 419

Group type: COMPARATOR
Intervention: Individual protein model
Number of subjects: 419

Group type: COMPARATOR
Intervention: Individual imaging model
Number of subjects: 419
Study: 39482712

Group type: EXPERIMENTAL
Intervention: Citrus peel extract (400 mg containing 3.0 mg of naringenin and 0.1 mg of auraptene)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Citrus peel extract
Number of subjects: 80
Study: 39482774

Group type: EXPERIMENTAL
Intervention: NSS HVA (defined as low carotid-femoral pulse wave velocity)
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: NSS HVA
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Non-NSS HVA (control group)
Number of subjects: 3234
Study: 39482930

Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg) + bevacizumab (7.5 mg/kg) + platinum-based chemotherapy (once every three weeks for six cycles, followed by maintenance therapy for 12 months)
Number of subjects: 24